A biotechnology company designing immunotherapies for solid tumor cancers with a patient’s white blood cells is raising $80 million in its initial public offering or IPO. . . . → Read More: Cancer Immunotherapy Biotech Issues $80M IPO
|
|||||
       |
 Comments are closed  Finance  biomedical, biotechnology, cancer, clinical trials, equity, FDA, investment, IPO, licensing, pharmaceuticals, venture capital 
(Myriams-Fotos, Pixabay. https://pixabay.com/photos/milk-splash-drops-food-liquid-4755234/) 31 Oct. 2022. A developer of synthetic biology treatments for inflammatory and neurological disorders linked to the gut is becoming a public company through a special acquisition merger. Intrinsic Medicine Inc. in Seattle is joining with Phoenix Biotech Acquisition Corp. in Oakland, California, a special purpose acquisition company or SPAC, . . . → Read More: Gut-Brain Meds Developer Going Public in Merger Comments are closed Finance biomedical, biotechnology, clinical trials, entrepreneurs, equity, investment, IPO, life sciences, merger, pharmaceuticals, preclinical 
A creator of game therapies for cognitive impairments is becoming a publicly-traded company through a special purpose acquisition company or SPAC. . . . → Read More: Digital Mental Therapy Company to Go Public in Merger Comments are closed Finance, New products biomedical, computer science, engineering, equity, investment, IPO, life sciences, mathematics, medical device, merger, physical sciences, software 
A developer of synthetic antibodies for inflammatory and skin disorders is becoming a public company through a special purpose acquisition-merger. . . . → Read More: Synthetic Antibody Company Goes Public in $230M Merger Comments are closed Finance biomedical, biotechnology, clinical trials, entrepreneurs, equity, Europe, investment, IPO, merger, pharmaceuticals 
A company producing synthetic RNA for agricultural and biomedical applications is now a public company after a special-purpose acquisition. . . . → Read More: RNA Manufacturer Goes Public in $282M Merger Comments are closed Finance agriculture, biomedical, biotechnology, chemistry, Covid-19, entrepreneurs, equity, investment, IPO, life sciences, manufacturing, merger, physical sciences 
A company developing synthetic biology and engineering tools for biotechnology is becoming a public company through a special-purpose acquisition. . . . → Read More: Synthetic Bio Company Goes Public in $2.5B Merger Comments are closed Finance biotechnology, economics, engineering, entrepreneurs, equity, genomics, investment, IPO, life sciences, merger, pharmaceuticals
Zymergen Inc., a developer of materials made with synthetic biology for industrial products is raising $500 million in its initial public stock offering. . . . → Read More: Biomanufacturing Materials Company Issues $500M IPO One comment - (Comments are closed) Finance agriculture, biotechnology, chemistry, economics, engineering, equity, genomics, investment, IPO, life sciences, manufacturing, materials science, mathematics, physical sciences 
A company developing regenerative therapies with engineered stem cells for cancer and other diseases is raising $587.5 million in its initial public offering or IPO. . . . → Read More: Engineered Cell Therapy Company Issues $588M IPO One comment - (Comments are closed) Finance biomedical, biotechnology, equity, genomics, investment, IPO, life sciences, pharmaceuticals, preclinical, stem cells, university 
Total venture investments in dollars jumped to a new high in the U.S., while biotechnology remained the single hottest sector in 2020. . . . → Read More: 2020 Venture Funds Mixed, Biotech Keeps Sizzling One comment - (Comments are closed) Finance biotechnology, economics, equity, investment, IPO, merger, software, venture capital
A biotechnology company developing therapeutic antibodies for Covid-19 infections is raising $483 million in its initial public offering of common stock. . . . → Read More: Covid-19 Antibody Developer Raises $483M in IPO One comment - (Comments are closed) Finance biomedical, biotechnology, Canada, clinical trials, Covid-19, equity, FDA, investment, IPO, NIH, pharmaceuticals |
||||
|
Copyright © 2023 Technology News and Literature - All Rights Reserved Powered by WordPress & Atahualpa |
|||||
RSS - Posts
You must be logged in to post a comment.